Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reevaluating the role of routine colonoscopy after acute diverticulitis: impact on colon cancer and advanced adenoma detection across age groups.

Proceedings (Baylor University. Medical Center)·2026
Same author

Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis.

Digestive diseases and sciences·2026
Same author

THREE-MONTH OUTCOMES OF ISCHEMIC COLITIS IN ANOREXIC VS NON-ANOREXIC PATIENTS: A PROPENSITY-MATCHED COHORT STUDY.

Arquivos de gastroenterologia·2026
Same author

THE DOUBLE BURDEN OF CIRRHOSIS AND ACUTE PANCREATITIS: AMPLIFIED RISKS FOR NUTRITIONAL AND GASTROINTESTINAL COMPLICATIONS.

Arquivos de gastroenterologia·2026
Same author

Does aspirin worsen Crohn's disease outcomes? A multicenter propensity-matched cohort study.

Proceedings (Baylor University. Medical Center)·2026
Same author

Endoscopic Ultrasound as a Diagnostic Tool in Obscure Gastrointestinal Bleeding: Left Gastric Artery Pseudoaneurysm Mimicking Gastric Varices.

ACG case reports journal·2026
Same journal

THE IL-6/IL-10 INFLAMMATORY AXIS AND PROGNOSIS OF CIRRHOSIS-ASSOCIATED HEPATOCELLULAR CARCINOMA: A NARRATIVE REVIEW.

Arquivos de gastroenterologia·2026
Same journal

EVALUATION OF CLINICAL ASPECTS OF PATIENTS UNDERGOING SACRAL NEUROMODULATION FOR FECAL INCONTINENCE: A RETROSPECTIVE MULTICENTER STUDY.

Arquivos de gastroenterologia·2026
Same journal

TRENDS AND RESEARCH FRONTIERS ON GUT MICROBIOTA AND STUNTING: A BIBLIOMETRIC INSIGHT FROM 2009 TO 2025.

Arquivos de gastroenterologia·2026
Same journal

MODULATING OXIDATIVE STRESS AND INFLAMMATION: SODIUM BUTYRATE'S THERAPEUTIC PROMISE IN EXPERIMENTAL COLITIS.

Arquivos de gastroenterologia·2026
Same journal

ACCURACY OF ULTRASOUND FOR SARCOPENIA ASSESSMENT IN DIGESTIVE TRACT CANCER PATIENTS.

Arquivos de gastroenterologia·2026
Same journal

SAFETY AND EFFECTIVENESS OF BLUE EYE HYPERTONIC SOLUTION VERSUS SALINE SOLUTION IN THE TREATMENT OF FLAT COLONIC LESIONS: A RANDOMIZED CLINICAL TRIAL.

Arquivos de gastroenterologia·2026
See all related articles

Related Experiment Video

Updated: Jun 11, 2026

Extended 78% Hepatectomy in a Mouse Surgical Model
05:25

Extended 78% Hepatectomy in a Mouse Surgical Model

Published on: May 24, 2024

GLP-1 AND CIRRHOSIS: EFFECTS ON MORTALITY AND LIVER-RELATED COMPLICATIONS.

Chidera N Onwuzo1, Odusanya Kikunlore Elijah2, Fnu Alvina1

  • 1SUNY Upstate Medical University, Internal Medicine Department, Resident Physician, Syracuse, NY, USA.

Arquivos De Gastroenterologia
|June 10, 2026
PubMed
Summary
This summary is machine-generated.

Glucagon-like peptide-1 (GLP-1) analogs significantly reduce mortality and complications like hepatic encephalopathy and hepatorenal syndrome in cirrhosis patients. This therapy also lowers the risk of portal hypertensive bleeding, potentially decreasing hospitalizations.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Experiment Videos

Last Updated: Jun 11, 2026

Extended 78% Hepatectomy in a Mouse Surgical Model
05:25

Extended 78% Hepatectomy in a Mouse Surgical Model

Published on: May 24, 2024

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Area of Science:

  • Hepatology and Gastroenterology
  • Pharmacology and Therapeutics

Background:

  • Cirrhosis presents severe complications including hepatic encephalopathy (HE), hepatorenal syndrome (HRS), and variceal bleeding.
  • Glucagon-like peptide-1 (GLP-1) analogs show promise in mitigating liver inflammation and cirrhosis-related issues.

Purpose of the Study:

  • To investigate the impact of GLP-1 analog therapy on mortality and clinical outcomes in patients diagnosed with cirrhosis.
  • To assess the efficacy of GLP-1 analogs in managing key cirrhosis complications.

Main Methods:

  • A retrospective analysis of the TriNetX research network cohort was performed.
  • Patients diagnosed with cirrhosis who initiated GLP-1 analog therapy were identified and propensity matched (1:1) for confounding variables.
  • Cox proportional hazards regression analysis was used to evaluate outcomes including all-cause mortality, HE, HRS, and portal hypertensive bleeding.

Main Results:

  • GLP-1 analog use was linked to a significant reduction in all-cause mortality (HR 0.374).
  • Treatment with GLP-1 analogs showed a decreased risk for hepatic encephalopathy (HR 0.900) and hepatorenal syndrome (HR 0.554).
  • A notable reduction in portal hypertensive bleeding events was observed in GLP-1 users (HR 0.487).

Conclusions:

  • GLP-1 analog therapy is associated with substantially lower all-cause mortality and fewer cirrhosis-related complications.
  • The observed decrease in portal hypertensive bleeding may lead to a reduction in patient hospitalizations.